Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Biomarkers of Alzheimer’s disease (AD) progression are needed to support the development of urgently needed disease modifying drugs. We employed a SOMAscan assay for quantifying 1,001 proteins in blood samples from 90 AD subjects, 37 stable mild cognitive impaired (MCI) subjects, 39 MCI subjects converting to AD within a year and 69 controls at baseline and one year follow up. We used linear mixed effects models to identify proteins changing significantly over one year with the rate of cognitive decline, which was quantified as the reduction in Mini Mental State Examination (MMSE) scores. Additionally, we investigated proteins changing differently across disease groups and during the conversion from MCI to AD. We found that levels of proteins belonging to the complement cascade increase significantly in fast declining AD patients. Longitudinal changes in the complement cascade might be a surrogate biomarker for disease progression. We also found that members of the cytokine-cytokine receptor interaction pathway change during AD when compared to healthy aging subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“A number of studies have previously identified cytokine proteins as being predictive of a clinical AD diagnosis and progression from MCI to AD [6, 18, 34, 35].”
BackgroundTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
Self-citationAlzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223 · cited 2×
“As we had longitudinal measures for only a subset of samples (69 controls, 37 ‘stable’ MCI patients (MCIs), 39 patients with MCI converting to AD within a year (MCIc), and 90 AD patients) cross-sectional results for the complete data set comprising protein measures for 691 subjects (211 controls, 106 MCI patients, 43…”
ResultSelf-citationPlasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Soares, H. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1070 · Cited by 218
Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease
Leung, R., Proitsi, P., Simmons, A., Lunnon, K., Güntert, A., Kronenberg, D., Pritchard, M., Tsolaki, M., Mecocci, P., Kloszewska, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064971 · Cited by 160 · cited 1×
“[36] investigated plasma levels of cytokines changing with the rate of cognitive decline.”
BackgroundSelf-citationPlasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
Kiddle, S. J., Thambisetty, M., Simmons, A., Riddoch-Contreras, J., Hye, A., Westman, E., Pike, I., Ward, M., Johnston, C., Lupton, M. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044260 · Cited by 100
Self-citationChemokines and brain functions
Banisadr, G., Rostene, W., Kitabgi, P., & Parsadaniantz, S. (2005) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010054022097 · Cited by 93
Cited by
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Simrén, J., Leuzy, A., Karikari, T. K., Hye, A., Benedet, A. L., Lantero‐Rodriguez, J., Mattsson‐Carlgren, N., Schöll, M., Mecocci, P., Vellas, B., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12283 · Cited by 340
Self-citationLarge-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk
Walker, K. A., Chen, J., Zhang, J., Fornage, M., Yang, Y., Zhou, L., Grams, M. E., Tin, A., Daya, N., Hoogeveen, R. C., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00064-0 · Cited by 212
Tin, A., Yu, B., Ma, J., Masushita, K., Daya, N., Hoogeveen, R. C., Ballantyne, C. M., Couper, D., Rebholz, C. M., Grams, M. E., et al. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.027086 · Cited by 106
Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
Sumner, I. L., Edwards, R. A., Asuni, A. A., & Teeling, J. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00254 · Cited by 24
Serum proteomics reveals APOE dependent and independent protein signatures in Alzheimer’s disease
Frick, E. A., Emilsson, V., Jonmundsson, T., Steindorsdottir, A. E., Johnson, E. C. B., Puerta, R., Dammer, E. B., Shantaraman, A., Cano, A., Boada, M., et al. (2023) · doi:10.1101/2023.11.08.23298251 · Cited by 3
Metadata
- Authors
- Sattlecker, M., Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., on behalf of the AddNeuroMed Consortium, & Dobson, R. J.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2015-11-23
- Volume
- 49
- Issue
- 4
- Pages
- 1105-1114
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2180365616
- Cited by
- 36
- References
- 9
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.